Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma

Launched by HOSPICES CIVILS DE LYON · Mar 26, 2021

Keywords

ClinConnect Summary

This clinical trial, called the SCITH-MESO study, is focused on understanding malignant pleural mesothelioma (MPM), a rare type of cancer that affects the lining of the lungs and is often linked to asbestos exposure. The researchers aim to gather larger tissue samples from patients during a routine surgery called VATS (Video-Assisted Thoracoscopic Surgery) to study the genetic and biological characteristics of the tumors. By collecting these samples, the study hopes to create a valuable tissue bank that can help improve our understanding of this difficult-to-treat cancer.

To participate in this trial, individuals must be over 18 years old and have a suspected diagnosis of MPM that requires a VATS biopsy, confirmed by a team of cancer specialists. Potential participants should also be able to understand the study's goals and provide informed consent. However, individuals who are pregnant, have certain mental health conditions, or are under legal protection cannot participate. If eligible, participants can expect to contribute to important research that could lead to better treatments for mesothelioma in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age \>18
• • suspected MPM requiring VATS biopsy after multidisciplinary oncologic board validation
• • patient able to understand study objectives and able to give an informed consent
• • patient affiliated to an healthcare society.
• Exclusion Criteria:
• • pregnancy
• • mental disease, psychiatric disorder
• • patient under protection regimen